Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.

Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia.

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.

Surgical and radiotherapeutic approaches for myelofibrosis with myeloid metaplasia.

PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis.

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases.